Pacira Pharmaceuticals Stock
Price
Target price
€20.00
€20.00
-
-
-
€30.06
28.11.25 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 30 € shows a positive potential of 50.0% compared to the current price of 20.0 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | - | 4.124% | 11.602% | 31.169% | 9.189% | -56.466% | -61.524% |
| Twist Bioscience Corp | 0.590% | 11.214% | -4.898% | -39.659% | -39.711% | 13.785% | -71.723% |
| Rockwell Medical Inc. | 4.660% | 11.240% | -14.592% | -60.707% | -59.499% | -18.350% | -91.003% |
| Vericel Corp. | -0.580% | 7.407% | 10.828% | -36.147% | -36.147% | 71.767% | 65.872% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat